The USFDA has accepted the New Drug Application (NDA)/Common Technical Document (eCTD) submitted by
Anesiva, Inc. (Nasdaq:
ANSV) for the marketing clearance of
Zingo™ for the treatment of pain associated with intravenous cannulation and venipuncture procedures in children.
Zingo™ is a needle-free system that delivers lidocaine powder into the epidermis of the skin and provides analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in pediatric populations and busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options.
Anesiva, Inc. is a late-stage biopharmaceutical company aspiring to become a eader in the development and commercialization of novel pain therapeutics.
Read the full press release.
.jpg)
Comment Preview